News Article | February 20, 2017
According to a new market research report "Apheresis Market by Product (Plasma & Component Separator, Hemoperfusion, and Disposable), Procedure (Therapeutic, Photopheresis, and Donor), Application (Plasmapheresis, Plateletpheresis), Technology (Centrifuge, Membrane Separation) - Global Forecast to 2021" published by MarketsandMarkets, the global market is projected to reach USD 2.06 Billion by 2021, at a CAGR of 7.7% from 2016 to 2021. Browse 174 market data Tables and 47 Figures spread through 212 Pages and in-depth TOC on "Apheresis Market" Early buyers will receive 10% customization on this report. The rising incidence of chronic lifestyle diseases such as diabetes, kidney disorders, & respiratory diseases, increasing demand for blood components, and favorable reimbursement scenario are the key factors driving the growth of the market. However, scarcity of qualified donors and the high cost of apheresis machines & procedures are restraining the growth of this market. In this report, the market is majorly segmented by product, procedure, technology, application, and region. Based on product, the market is segmented into devices and disposables. The disposables segment accounted for the largest share and will be the fastest growing market during the forecast period. This is attributed to the increasing demand for disposables and rising preference for apheresis blood collection. On the basis of procedure, the market is segmented into automated/donor apheresis and therapeutic apheresis. Therapeutic apheresis is further segmented into therapeutic plasma exchange (TPE), therapeutic cytapheresis, photopheresis, and extracorporeal immunoadsorption (ECI). In 2015, therapeutic plasma exchange segment accounted for the largest share of the market. The large share of this segment is attributed to the increasing prevalence and incidence of various blood disorders such as sickle-cell anemia and leukemia. The photopheresis segment is expected to register the highest CAGR during the forecast period due to the increasing demand for photopheresis in organ transplant rejection treatment. In 2015, North America accounted for the largest share of the market, followed by Europe. The presence of established distribution channels, growing applications of apheresis products in plasma collection and fractionation, and rising number of hemophilic patients are driving the growth of the North American apheresis market. The Asia-Pacific region is expected to witness the highest growth in this market majorly due to improving healthcare infrastructure and growing economies in China and India. In addition, manufacturers are increasingly focusing on strengthening their presence in emerging APAC countries. The global Apheresis Market is highly competitive in nature, with the top five companies accounting for the major market share in 2015. Some of the key players in this market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), Cerus Corporation (U.S.), B. Braun Melsungen AG (Germany), HemaCare Corporation (U.S.), Kaneka Corporation (Japan), and Nikkiso Co., Ltd. (Japan). These leading players primarily focused on product launches, acquisitions, agreements, collaborations, partnerships, and expansions to help growth in the market. U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain-Barré Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021 MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
News Article | May 11, 2017
"Both the Mirasol PRT system for WB and a hemovigilance program are important components of the collaboration for our continued drive towards improving blood safety in Ghana," said Justina Ansah, MD, CEO of the National Blood Service of Ghana (NBSG). "I'm excited to see the direct results of this collaboration, which we hope will help to further reduce the risk associated with blood transfusions in Ghana." Terumo BCT, a Terumo Corporation company, worked closely with the NBSG on initiatives for blood safety to complete the African Investigation of the Mirasol System (AIMS) clinical study at the Komfo Anokye Teaching Hospital in Kumasi. The study demonstrated a significant reduction in malaria transmissions through blood transfusion using whole blood treated with the Mirasol PRT system. As a result, the Mirasol PRT system for WB was CE marked in September 2015 and was approved for use by the Ghana FDA in August 2016. JICA and Terumo Corporation also have a history of success. "In 2013, JICA and Terumo successfully collaborated to broaden transradial intervention (TRI) in Latin America," said Takashi Baba, director of the Private Sector Partnership Division, JICA. "We believe this transfusion program, based on Japanese technology, will help Ghana address some key transfusion challenges such as malaria, which we do not face in Japan." The Mirasol PRT system for WB uses a combination of riboflavin (vitamin B2) and ultraviolet light to reduce the risk of exposure to pathogens and to inactivate white blood cells in whole blood for transfusion. "We're proud of this collaborative global effort to directly address the safety of the blood supply in Ghana," said David Perez, president and CEO of Terumo BCT. "We look forward to working with the blood center staff to implement Mirasol PRT as part of their daily efforts to help ensure patients in need have access to safer transfusions." Healthcare professionals in more than 70 centers across 20 countries in Europe, the Middle East, South America, Central America and Asia are currently using the Mirasol PRT system. As part of an effort to seek U.S. FDA approval for Mirasol-treated blood products, Terumo BCT is initiating clinical trials identified as MIPLATE and PRAISE to support these submissions. Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. JICA, an independent administrative corporation established under the International Cooperation Organization Act, is dedicated to enhancing the economy and society. JICA partners with companies and organizations throughout the world to advance understanding through research and address health issues with equipment, goods and emergency aid. Those working with JICA to support this initiative include the Ghana Ministry of Health, NBSG, Korle-bu Teaching Hospital in Accra, Komfo Anokye Teaching Hospital in Kumasi, Terumo Corporation and Terumo BCT. 1Adjei AA, Kuma GK, Tettey Y, et al. Bacterial contamination of blood components in three major blood transfusion centers, Accra, Ghana. Jpn J Infect Dis. 2009;62(4):265-269. 2Freimanis G, Sedegah M, Owusu-Ofori S, Kumar S, Allain J-P. Investigating the prevalence of transfusion transmission of Plasmodium within a hyperendemic blood donation system. Transfusion. 2013;53(7):1429-1441. 3Nkruma B, Owusu M, Frempong HO, Averu P. Hepatitis B and C viral infections among blood donors from rural Ghana. Ghana Med J;2011:45(3):97-100. 4Ampofo W, Nii-Trebi N, Ansah J, et al. Prevalence of blood-borne infectious diseases in blood donors in Ghana. J Clin Microbiol. 2002;40(9):3523-3525.
News Article | May 17, 2017
"This study is intended as a step towards improving transfusion therapy and transfusion safety in the U.S.," said Sherrill Slichter, MD, principal investigator from Bloodworks Northwest and lead investigator for the MIPLATE clinical trial. "We're excited to be a part of this study that hopefully will lead to measures that could further protect the nation's blood supply from certain complications and threats of blood transfusions." MIPLATE is a multi-center, controlled, randomized, non-inferiority study designed to evaluate the clinical effectiveness of Mirasol-treated apheresis Platelets in Plasma versus standard apheresis Platelets in Plasma in patients with hypoproliferative thrombocytopenia. This condition is characterized by low platelet count in patients with compromised bone marrow due to hematologic malignancies or treatments such as chemotherapy. "In addition to being designed to support our PMA application for U.S. approval, this study is an important part of our ongoing efforts to advance blood safety and patient care," said Palani Palaniappan, Executive Vice President of Innovation & Development, Terumo BCT. "With a better clinical understanding of technologies like the Mirasol PRT system in the U.S., we can bring our customers a safe, simple and effective solution to help protect their patients from pathogens." About Mirasol PRT System The Mirasol PRT system is CE marked for platelets, plasma, and whole blood and is in use in approximately 20 countries and 140 blood centers throughout Europe, the Middle East, Africa, Asia and Latin America. The system is for investigational use only in the U.S. and Canada and is available in other select countries. About Terumo BCT Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600013C. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/terumo-bct-announces-enrollment-of-the-first-patient-in-its-us-clinical-trial-designed-to-study-platelets-treated-with-the-mirasol-pathogen-reduction-technology-prt-system-300458904.html
News Article | May 16, 2017
SA-BRC is pleased to announce the initiation of research on "Global Apheresis Systems Market". -- Apheresis enables simultaneous separation of blood components and delivery of unused components back to donor's body. Apheresis is widely used for collecting blood components such as platelets and plasma. Based on applications, the market is segmented into plateletpheresis, erythrocytapheresis, plasmapheresis, LDL apheresis, leukapheresis, photopheresis, lymphapheresis, and extracorporeal immunoadsorption.Plasmapheresis is the most attractive market segment accounting for largest market share. Myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus are some of the major disorders treated with plasmapheresis. Photopheresis involves treatment with photosensitizing agent and subsequently irradiated with specified wavelengths. Photopheresis is an U.S. Food and Drug Administration (FDA) approved procedure for the treatment of advanced cutaneous T-cell lymphoma. The treatment is also effective in treatment of psoriasis, multiple sclerosis, rheumatoid arthritis, and scleromyxedema.Request Free Report Sample@ http://www.sa- brc.com/Global- Apheresis-Systems- Market-Ass... Wide range of apheresis technology applications has supported the market growth to a large extent. External supply of blood component is required in various clinical manifestations, and is an important part of success of treatment prescribed. Diseases related to hematology, neurology, oncology, and renal diseases are most prominent areas requiring blood and blood components. Traumatic injuries and open surgeries involving severe loss of blood also require supply of external blood components for faster patient recovery. American Red Cross Association states that more than 35,000 units of red blood cells (RBC) are required every day in the U.S. alone. Furthermore, there has been a surge in application of therapeutic apheresis in oncology procedures. Scientists are also engaged in conducting continuous research activities to discover novel treatment methods for critical illness involving application of apheresis. Majority of these include autoimmune diseases, cancer, and hereditary blood disorders. These factors would act as initial drivers for the global apheresis market. However, scarcity of blood donors and histocompatibility pose a challenge.North America has well established distribution channels, and large installed base, which makes it the market leader from geographical standpoint. Europe and Asia region comprise 30% to 35% of the global market share. The market would expand as hematology research advances in near future, and adoption and awareness regarding apheresis application percolates to developing nations. Although this would also require investment from the side of healthcare service providers, the demand for better healthcare service would assist in adoption of this technology. Market for apheresis systems is largely consolidated;60% market share being occupied by top five players. Fresenius Medical Care, Terumo BCT, Inc., Medica S.p.A., Haemonetics Corporation, and Therakos, Inc. are some of the leading players in the apheresis market.Request For TOC@ http://www.sa- brc.com/Global- Apheresis-Systems- Market-Ass... NOTE: This report is currently under research and will be made available to clients on request.
News Article | May 23, 2017
· The global apheresis equipment market is expected to reach USD 3.7 billion by 2024, according to a new report by Grand View Research, Inc. · The apheresis equipment industry is expected to be impacted by factors such as rising demand for plasma, platelets and other blood components, increasing incidence of chronic illnesses, presence and development of ideal reimbursement policies across various regions, and supportive government initiatives. · Growing incidence of blood related disorders leading to the rise in demand for platelets and plasma is expected to serve the market as a high impact rendering driver. · Disposable apheresis kits are anticipated to dominate the product segment by 2024. · The photopheresis procedure is anticipated to witness lucrative growth owing to its rising demand in treatment. The global apheresis equipment market is expected to reach USD 3.7 billion by 2024, according to a new report by Grand View Research, Inc. The apheresis equipment industry is expected to be impacted by factors such as rising demand for plasma, platelets and other blood components, increasing incidence of chronic illnesses, presence and development of ideal reimbursement policies across various regions, and supportive government initiatives. The U.S. Federal Government has been very involved in the funding of apheresis research through its benefit programs such as Medicare, Medicaid, veterans' health administration military and employee insurance programs. Medicare provides coverage for apheresis regardless of whether the procedure is performed in a hospital or a blood center. In addition, private insurers have recently begun to closely examine apheresis procedures and issue policy statements pertaining to coverage. Growing incidence of blood related disorders leading to the rise in demand for platelets and plasma is expected to serve the market as a high impact rendering driver. The industry is also expected to be driven by technology innovations aimed at delivering relatively more effective and faster results. Healthcare practitioners and researchers are now in the need for devices requiring minimum human intervention and introduction of fully automatic apheresis equipment with enhanced displays is expected to improve usage rates. Further Key Findings From the Study Suggest: Disposable apheresis kits are anticipated to dominate the product segment by 2024. Bulk volume purchase associated with these products is predicted to govern their growth.A single cycle of apheresis procedure consumes multiple disposable sub parts which is responsible for comparatively larger market volume as compared to apheresis machines. The photopheresis procedure is anticipated to witness lucrative growth owing to its rising demand in treatment. The procedure is approved for treatment of solid organ transplant rejection, scleroderma, type 1 diabetes, pemphigus vulgaris, lichen planus &atopic dermatitis, and cutaneous T-cell lymphoma. Another procedure expected to gain lucrative share is erythrocytapheresis. The procedure also finds application in blood donation procedures where it is widely used for separating two units of blood, known as double red cell apheresis. Rising incidence rates of genetic disorders such as sickle cell anemia is expected to drive market growth by widening the patient base. Asia Pacific is anticipated to witness the fastest growth over the forecast period. Presence of high unmet needs and rapidly increasing demand for platelets in the emerging Asia Pacific and Latin American markets is expected to serve this market as future growth opportunities. For example, in July, 2014, India witnessed a rapid rise in demand for platelets owing to an increased incidence rate of dengue. Key players of this industry include Fresenius Kabi; Haemonetics; Terumo BCT; Therakos, Inc.; Asahi Kasei Kuraray Medical Co Ltd; and B. Braun Melsungen AG. Strategies promoting faster distribution and development of efficient supply chain are being incorporated by the players. Read the full report: http://www.reportlinker.com/p04523048/Apheresis-Equipment-Market-Analysis-By-Application-Renal-Diseases-Hematology-Neurology-By-Procedure-Plasmapheresis-LDL-Apheresis-Plateletpheresis-Leukapheresis-Photopheresis-Erythrocytapheresis-And-Segment-Forecasts.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com __________________________ Contact Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/apheresis-equipment-market-is-expected-to-reach-usd-37-billion-by-2024-300461963.html
News Article | May 16, 2017
— Increasing incidence of cardiovascular disorders, demand for automated blood component separation procedures, adoption of technologically advanced automated products, government focusing on healthcare infrastructure and rise in the number of platelet donors are fueling the market growth. However, histocompatibility issues, high cost of equipment and lack of trained technicians will hamper market growth. Plasmapheresis segment accounted for the largest market share of the apheresis procedure market due to growing incidence of hematological disorders. Apheresis disposable kits is the largest segment in the total apheresis equipment product market as single use products are in high demand along with high usage volume. Neurology segment is projected to witness the fastest growth under application as individuals are affected with multiple sclerosis. North America is the leading market because of the presence of sophisticated healthcare infrastructure. Asia Pacific is anticipated to be the fastest growing market due to Increasing prevalence of blood disorders and plasma products in China, Japan, Australia, Korea and India. Some of the key players in global Apheresis Equipment market are Asahi Kasei Kuraray Medical Co., Ltd., Fenwal, Inc., Braun Melsungen AG, Cerus Corporation, Fresenius Se & Co. KGAA, Medica SpA, Kaneka Corporation, Nikkiso Co., Ltd, Kawasumi Laboratories Inc, Therakos, Inc., HemaCare Corporation, Haemonetics Corporation and Terumo BCT, Inc. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 8 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com
News Article | May 24, 2017
Terumo BCTs Spectra Optia® Apheresis System, ein FDA-zugelassenes und CE-gekennzeichnetes Gerät für die therapeutische Apherese und für Verfahren zur Zellenentnahme, wird aktuell in Krankenhäusern und Apherese-Zentren auf der ganzen Welt eingesetzt. Spectra Optia wird in die Forschungsbemühungen von CANCER-ID einbezogen, die diagnostische Leukapherese (DLA) bezüglich ihrer Tauglichkeit zum Erfassen und zur Gewinnung größerer Mengen von ZTZs zu bewerten1. Durch diese Forschung kann dem Spectra Optia-System womöglich in zukünftigen Diagnoseprozessen eine Rolle zugeschrieben werden. Informationen zur Innovative Medicines Initiative (IMI) Dieses CANCER-ID-Projekt hat Fördermittel von der Innovative Medicines Initiative 2 Joint Undertaking unter der Fördernummer No 115749 erhalten. Dieses gemeinsame Unterfangen erhält Unterstützung vom Horizon 2020 Forschungs- und Innovationsprogramm der Europäischen Union sowie von der EFPIA. IMI arbeitet an einer Verbesserung der Gesundheit durch die beschleunigte Entwicklung von und Patientenzugang zu innovativen Medikamenten, insbesondere in Gebieten, wo ein ungedeckter medizinischer oder sozialer Bedarf besteht. Dies wird durch eine Kollaboration mit den Hauptakteuren ermöglicht, die in Gesundheitsforschung involviert sind, einschließlich Universitäten und anderen Branchen, Klein- und mittelständischen Unternehmen (KMUs), Patientenorganisationen und Regulierungsbehörden für Medikamente.
News Article | May 24, 2017
DENVER--(BUSINESS WIRE)--Colorado BioScience Association (CBSA) announces the appointment of Scott Larson as its new chairman of the board of directors. Larson, Senior Vice President of Legal and General Counsel for the global medical device innovator, Lakewood-based Terumo BCT, will lead CBSA for a two-year term. Larson replaces outgoing chair Mark Spiecker, who will continue to serve on the CBSA board and executive committee through 2017. Joining Larson and Spiecker in executive committee positions are: Scott Larson, Chairman of the Board for CBSA, said: “The Colorado BioScience Association supports our fast-growing sector by focusing efforts on the themes that matter most to our members, including increasing access to capital, highlighting their success stories, and connecting talent within Colorado biosciences. I’m proud to work with our board to directly contribute to the vitality of our bioscience sector.” The 30-person CBSA board of directors is comprised of representatives from the state’s biotechnology, medical device, diagnostic, pharmaceutical, ag bio, digital health, healthcare and research organizations. April Giles, President and CEO of CBSA said: “Our newest board members, all from commercial companies, represent a shift in our state’s bioscience sector. While Colorado is known for a thriving start-up community, several of our companies are moving from the emerging or mid-stage into the manufacturing stage. We’re pleased to welcome leaders from Silvergate Pharmaceuticals, Bio2Medical, AstraZeneca and Allosource to the Colorado Bioscience Association Board of Directors.” Board members commit to a three-year term and work in partnership with CBSA staff to support the growth of Colorado’s more than 720 bioscience companies. Names and biographies of the full board of directors are available on the CBSA website. Colorado BioScience Association champions life science. We serve as the hub of Colorado’s thriving bioscience sector by connecting innovators to funding, infrastructure, research and talent. From promising young companies to established corporations and institutions, we provide opportunities for networking, education and professional development. We grow the bioscience workforce and lead business expansion policies to advance the industry in our state. CBSA represents more than 350 member organizations, including biotechnology, pharmaceutical, medical device, diagnostic, ag bio and mobile digital health companies, research and academic institutions and service providers. Learn more about us at http://www.cobioscience.com.
News Article | May 24, 2017
La asociación público-privada tiene el objetivo de estandarizar y validar clínicamente los biomarcadores sanguíneos LAKEWOOD, Colorado, 24 de mayo de 2017 /PRNewswire/ -- Terumo BCT, una de las empresas más importantes de hemoderivados, aféresis terapéutica y tecnologías celulares, ha...
News Article | May 1, 2017
Em seu quarto ano, o Prêmio para o Desenvolvimento da Aférese da Terumo BCT é parte do compromisso de longo prazo de apoiar aqueles que aprimoram os cuidados ao paciente no uso da aférese terapêutica e coleções de células. A cada ano, o ganhador é escolhido por uma comissão externa global composta de importantes líderes de opinião. Sua decisão baseou-se nas considerações dos planos do AUH para o uso do prêmio, sua história de demonstração de liderança educacional e seu impacto para a comunidade. A comissão do subsídio da Terumo BCT 2016 foi composta por: A cada ano, o Prêmio para o Desenvolvimento da Aférese apresenta um foco diferente. Em 2016, concentrou-se na solução das dificuldades do acesso venoso. "Selecionar e garantir a abordagem apropriada ao acesso vascular é um desafio; aprimorar o acesso periférico pode levar à melhoria da experiência clínica e do paciente. É um privilégio homenagear as iniciativas de médicos, profissionais da saúde e operadores que continuam a aprimorar a experiência e os resultados de pacientes ao redor do mundo", disse Monte Smith, vice-presidente, sistemas terapêuticos globais da Terumo BCT. Pela primeira vez na história do Prêmio para o Desenvolvimento da Aférese, a Terumo BCT incluiu um defensor dos pacientes na comissão de avaliação. Ed Harris atua como diretor executivo e fellow de pesquisas no departamento de Imunologia e Microbiologia Médica da University of Wisconsin–Madison. Harris foi um paciente em mais de 365 procedimentos de aférese terapêutica, todos executados com acesso venoso periférico. Sobre a Terumo BCT A Terumo BCT, líder global em tecnologias celulares, aférese terapêutica e componentes sanguíneos, é a única empresa com a combinação exclusiva de coleções por aférese, processamento de sangue total manual e automatizado, e tecnologias de redução patogênica. Acreditamos que o sangue pode fazer ainda mais do que faz atualmente para pacientes. A convicção desse potencial nos inspira à inovação e fortalece nossa colaboração com os clientes.